181 related articles for article (PubMed ID: 18234715)
1. Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?
Saleem B; Mackie S; Quinn M; Nizam S; Hensor E; Jarrett S; Conaghan PG; Emery P
Ann Rheum Dis; 2008 Aug; 67(8):1178-80. PubMed ID: 18234715
[TBL] [Abstract][Full Text] [Related]
2. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
3. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
4. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
5. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.
Smolen JS; Han C; van der Heijde DM; Emery P; Bathon JM; Keystone E; Maini RN; Kalden JR; Aletaha D; Baker D; Han J; Bala M; St Clair EW;
Ann Rheum Dis; 2009 Jun; 68(6):823-7. PubMed ID: 18593759
[TBL] [Abstract][Full Text] [Related]
6. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Maini R; St Clair EW; Breedveld F; Furst D; Kalden J; Weisman M; Smolen J; Emery P; Harriman G; Feldmann M; Lipsky P
Lancet; 1999 Dec; 354(9194):1932-9. PubMed ID: 10622295
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
8. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN;
N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166
[TBL] [Abstract][Full Text] [Related]
9. Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist.
Bao J; Yue T; Li T; He DY; Bao YX
Int J Rheum Dis; 2016 Apr; 19(4):370-6. PubMed ID: 24798350
[TBL] [Abstract][Full Text] [Related]
10. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis.
Bejarano V; Conaghan PG; Quinn MA; Saleem B; Emery P
Rheumatology (Oxford); 2010 Oct; 49(10):1971-4. PubMed ID: 20595536
[TBL] [Abstract][Full Text] [Related]
11. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
12. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging.
Hirose W; Nishikawa K; Hirose M; Nanki T; Sugimoto H
Mod Rheumatol; 2009; 19(1):20-6. PubMed ID: 18762862
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy.
Niki Y; Takeuchi T; Nakayama M; Nagasawa H; Kurasawa T; Yamada H; Toyama Y; Miyamoto T
PLoS One; 2012; 7(5):e37447. PubMed ID: 22629396
[TBL] [Abstract][Full Text] [Related]
14. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
Rantalaiho V; Kautiainen H; Korpela M; Hannonen P; Kaipiainen-Seppänen O; Möttönen T; Kauppi M; Karjalainen A; Laiho K; Laasonen L; Hakola M; Peltomaa R; Leirisalo-Repo M;
Ann Rheum Dis; 2014 Nov; 73(11):1954-61. PubMed ID: 23908187
[TBL] [Abstract][Full Text] [Related]
15. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
[TBL] [Abstract][Full Text] [Related]
16. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
[TBL] [Abstract][Full Text] [Related]
18. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
[TBL] [Abstract][Full Text] [Related]
19. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
Smolen JS; van der Heijde DM; Aletaha D; Xu S; Han J; Baker D; St Clair EW
Ann Rheum Dis; 2009 Oct; 68(10):1535-40. PubMed ID: 18957487
[TBL] [Abstract][Full Text] [Related]
20. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
